Akero Therapeutics sees a significant leap! Positive results from its Phase 2b study for the drug Efruxifermin reported!
Reading Time: 3 minutes
The stock price of Akero Therapeutics (AKRO) surged by a stunning 97.52% to $51.72 by market close on Monday, January 27, 2025, after the company announced positive long-term results from a Phase 2b study of its liver drug Efruxifermin for the treatment of metabolic dysfunction associated with steatohepatitis, known as MASH, and presents a significant market opportunity. Liver cirrhosis due to MASH has a high mortality rate Liver cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis) is a life-threatening disease with a high...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
